In order to evaluate the efficacy and safety of fenofibrate in Turkish people, 249 primary hyperlipidemic subjects, aged 31 - 74 years (mean 54±7), were treated with onee-a-day 250 mg controlled release fenofibrate following a lipidlowering diet. The efficacy and safety parameters were measured at baseline, on the 8th and the 12th weeks of therapy. After a treatment of 12 weeks, a decrease by 14.8% (p<0.0001), 13% (p
Esmeray ACARTÜRK, Halis DÖRTLEMEZ, Esmeray ACARTÜRK, Halis DÖRTLEMEZ. Efficacy and Safety of Fenofibrate in Primary Hyperlipidemic Subjects. Turk Kardiyol Dern Ars. 2000; 28(2): 121-125
Manuscript Language: Turkish
Copyright © 2024 Archives of the Turkish Society of Cardiology